Navigation Links
ASU embarks on next phase of an effort to rapidly assess radiation dose
Date:10/6/2011

TEMPE, Ariz.--Arizona State University has announced today it is entering the next phase of a multi-million, multi-institutional research project to develop technologies that would rapidly measure an individual's level of exposure to radiation in the event of a radiological or nuclear incident.

The project will enter a $5 million contract option as part of a potential $35.44 million project funded by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to extend feasibility testing for the development of a prototype that will measure gene expression in individuals exposed to abnormal levels of radiation.

Currently, no rapid, FDA cleared, high-throughput system exists to measure the radiation dose of individuals within a large population.

"As Japan's tsunami and resulting nuclear crisis has demonstrated, there is an urgent societal need to rapidly assess an at risk population's exposure to radiation," said Lee Cheatham, PhD, deputy director of the Biodesign Institute and lead investigator of the project. "Our ultimate goal is to develop a diagnostic system that would ensure that medical responders have the information necessary to provide appropriate medical treatment and ensure human health and safety."

ASU will continue to oversee the research program management, coordination and integration necessary for effective development of the technology, which will develop a high-throughput system for radiation biodosimetry that is capable of processing a high volume of blood samples per day for gene expression analysis on an automated liquid handling and imaging platform consistent with FDA guidelines.

Developing the system requires utilizing a biomarker signature set based on gene expression markers. This set of markers will provide a distinct indicator for the level of absorbed radiation. Along with Biodesign Institute biomarker research expert Dr. Joshua LaBaer, director of the institute's Virginia G. Piper Center for Personalized Diagnostics, will be collaborators with extensive experience in researching radiation responsive genes and development of microassay reagents and imagers, including: Sally Amundson, PhD, at Columbia University Medical Center, Bruce Seligmann, PhD, founder and CSO at HTG Molecular Diagnostics, Inc. and Amelia Bartholomew, MD, MHP, FACS at University of Illinois, Chicago.

"We are honored to be part of this multi-institutional program and believe our work with ASU has further established HTG's dynamic offerings," said T.J. Johnson, Chief Executive Officer, HTG Molecular Diagnostics.

The ASU effort is part of a BARDA initiative to feed the pipeline for advanced development, manufacturing, and regulatory activities that would position ASU's biodosimetry device for potential use in human triage and treatment decisions.


'/>"/>

Contact: Joe Caspermeyer
joseph.caspermeyer@asu.edu
480-727-0369
Arizona State University
Source:Eurekalert

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Dr. Ronald E. Hawkins, vice president ... of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean ... Dr. Bell comes to Liberty from the Ohio University Heritage College of Osteopathic ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec ... it’s not if you will be attacked, but when.” However, he and many others ... health care. , Improvements in auditing and monitoring have taken security in health care ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... ... to The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite ... Medical District with easy access to Highway 121. , As the practice has grown, ...
(Date:2/24/2017)... ... , ... With ProGlass Prism users now have the ability to simulate prism ... position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, anchor ... Prism users are given the tools and effects to generate a fractal prismatic ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition of the "Menopause Drugs ... ... Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks ... What are the key drugs marketed for ... Menopause market? What are the unit prices and annual ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
Breaking Medicine Technology: